Advisory Board September 28, 2022

Lecanemab, an experimental Alzheimer’s drug developed by Eisai and Biogen, slowed cognitive and functional decline by 27% compared to a placebo in a new study—results that the drugmakers said were “highly statistically significant.”

3 big questions to ask after FDA’s historic Alzheimer’s drug approval

Details on the study

Similar to Aduhelm, Alzheimer’s drug lecanemab reduces abnormal clumps of beta amyloid, proteins that are typically a sign of Alzheimer’s disease.

According to a press release, the study—called CLARITY-AD—enrolled 1,795 patients with mild cognitive impairment caused by Alzheimer’s disease, or early-stage Alzheimer’s. Roughly a quarter of the participants were Hispanic and African American.

The patients were then tested using the Clinical Dementia Rating sum of boxes (CDR-SB), which measures six domains of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Survey / Study, Trends
Brazil’s plan for low-cost CAR-Ts
PacBio’s Repeat Expansion Panel, Owkin-Sanofi AI Take on Immunology, More
STAT+: Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful again
Moderna gets Blackstone backing for flu vaccine R&D
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Share This Article